Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=852 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
Kidney Transplantation
Primary: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy — 31; 68 Participants — p=<0.0001
Phase 4 N=20 Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
Kidney Transplant
Primary: Graft Survival — 13; 7 participants — p=0.849
Phase 3 N=194 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Phase 4 N=52 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
Kidney Transplantation
Primary: Number of Participants With Graft Survival at 12 Months — 18; 12 Participants
Phase 4 N=30 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Renal Transplant Rejection · Immunosuppression
Primary: Cytokines Evaluation — 380; 893; 763; 147 MFI — p=<0.05
Phase 4 N=30 Spironolactone After Liver Transplant
Transplant, Liver
Primary: Glomerular Filtration Rate (GFR) — 69; 64 ml/min/1.73m^2 — p=0.0001
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
Phase 2 N=527 Calcineurin Inhibitor Sparing After Kidney Transplantation
CNI Side Effects
Primary: Phase I: The Minimization of Negative Side Effects - Patient Survival — 99; 98 percentage of participants
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Phase 4 N=341 Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
Renal Function
Primary: Measured Glomerular Filtration Rate — 51.5; 47.8 mL/min/1.73m^2
Phase 4 N=394 ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
Renal Transplantation
Primary: Renal Function Assessed by Measured GFR (mGFR) — 46.02; 48.00; 46.60 mL/min/1.73m^2 — p=0.6332
N/A N=781 Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
Phase 3 N=13 Belatacept Therapy for the Failing Renal Allograft
Failing Renal Allograft
Primary: Number of Participants With Donor-specific Antibody Formation — 3; 4 Participants
Phase 2 N=33 Tocilizumab for Renal Graft Inflammation
Late Complication From Kidney Transplant
Primary: Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months — 3; 10 Participants — p=0.033
Phase 2 N=15 Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
Phase 3 N=709 Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
Kidney Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) — 64.1; 61.5; 58.4 mL/min/1.73m^2
Phase 2 N=1 C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
Antibody Mediated Rejection of Kidney Transplant
Primary: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) — 1 Participants
Phase 3 N=32 Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
Phase 1 N=16 Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
Kidney; Complications, Allograft
Primary: Baseline eGFR (Estimated Glomerular Filtration Rate) — 30.04; 30.04 mL/min/1.73 m2
Phase 2 N=2 Renal Allograft Tolerance Through Mixed Chimerism
End Stage Renal Disease
Primary: Successful Withdrawal of Immunosuppressive Therapy — 2 Participants
N/A N=40 Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation
Primary Renal Transplant
Primary: Number of Participants With Biopsy Proven Rejection — 2; 7 participants
Phase 3 N=203 Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Liver Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) — 87.9; 84.1 mL/min
N/A N=30 Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min
N/A N=73 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
Phase 2 N=5 Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
Graft Rejection · Kidney Disease
Primary: Number of Patients With Renal Allograft Rejection — 5 participant
Phase 3 N=802 Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen
Kidney Transplantation
Primary: GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen — 63.03; 68.59; 63.08 ml/min/1.73m² — p=< 0.0001
Phase 4 N=63 Optima: Optimizing Prograf Therapy in Maintenance Allografts II
Kidney Transplantation
Primary: Renal Function in Patients Converted From Cyclosporine to Prograf — 0.05; 0; 0.10 Change in serum creatinine (mg/dL)
Phase 2 N=10 Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Antibody-mediated Rejection · Kidney Transplant; Complications · Transplant Glomerulopathy
Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants